AI Labs

Isomorphic Labs

Medium62% confidenceProfile verified Jul 22, 2026
OverviewMore SignalsSourcesDependency mapStoryMilestones

An Alphabet-spun-out AI drug discovery company built on DeepMind's AlphaFold protein-structure technology, which raised a $2.1 billion Series B round in May 2026 led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Isomorphic Labs holds multi-drug R&D alliances with Eli Lilly, Novartis, and Johnson & Johnson, and is targeting its first human clinical trials by late 2026.

⚡

Additional Intelligence Signals

Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

3 sources · 61% avg. source confidence

  • BioSpace / PR Newswire — Isomorphic Labs raises $2.1B Series B to scale AI drug design engine74% source confidence
  • Isomorphic Labs corporate site — Isomorphic Labs' pharma alliance portfolio spans Lilly, Novartis, and J&J60% source confidence
  • pharmaphorum — Isomorphic Labs details use of Series B proceeds: clinical trials, international hiring48% source confidence

Correlated Activity

Both Isomorphic Labs and AI Materials Discovery — which it depends on — are showing accelerating Activity at the same time (1 recorded change for AI Materials Discovery in the last 90 days).

Timing correlation only — not evidence of a causal link

⚡

Dependency Map

What Isomorphic Labs depends on below, and who depends on Isomorphic Labs above — click any node to make it the new center, 2 levels deep.

2 levels3 levels5 levels

Connection type

Investment
Dependency
Supply Chain
Development
Enablement
Competition / Other
Succession

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

May 2026: $2.1B Series B round→May 2026: Isomorphic Labs raises $2.1B Series B to scale AI drug design engine→May 2026: Isomorphic Labs' pharma alliance portfolio spans Lilly, Novartis, and J&J→Jul 2026: Isomorphic Labs details use of Series B proceeds: clinical trials, international hiring

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

⚡

Isomorphic Labs's Timeline

A sourced, dated history of Isomorphic Labs's key moments — founding to present.

  1. Jan 2021 · Spun out of Alphabet/DeepMind

    Isomorphic Labs was spun out of Alphabet, building on DeepMind's AlphaFold protein-structure prediction technology to pursue AI-driven drug discovery.

  2. May 2026 · $2.1B Series B round

    Isomorphic Labs raised a $2.1 billion Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, to scale its IsoDDE AI drug design engine and expand its therapeutic pipeline toward the clinic.